Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
…, L Barr, J Benoit, B Carste, J Choe, M Dunstan… - Science, 2021 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …
[HTML][HTML] Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
…, MJ Smith, BG Ladner, L Porterfield, M Dunstan… - Nature medicine, 2023 - nature.com
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …
Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent …
…, O Yu, JC Nelson, PT Starkovich, M Dunstan… - Vaccine, 2007 - Elsevier
In this dose-ranging study 220 seniors who had received the 23-valent pneumococcal
polysaccharide (PnPS) vaccine at least 5 years prior to enrollment were assigned to receive one …
polysaccharide (PnPS) vaccine at least 5 years prior to enrollment were assigned to receive one …
SARS-CoV-2 variant vaccine boosters trial: preliminary analyses
…, MJ Smith, BG Ladner, L Porterfield, M Dunstan… - MedRxiv, 2022 - medrxiv.org
Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by
emerging variants including Omicron subvariants. This study evaluated safety and …
emerging variants including Omicron subvariants. This study evaluated safety and …
[HTML][HTML] Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant …
…, M Smith, B Ladner, L Porterfield, M Dunstan… - Research …, 2023 - ncbi.nlm.nih.gov
… Angela Branche, Nadine Rouphael, David Diemert, Ann Falsey, Cecilia Losada, Lindsey
(R) Baden, Sharon Frey, Jennifer Whitaker, Susan Little, Evan Anderson, Emmanuel Walter …
(R) Baden, Sharon Frey, Jennifer Whitaker, Susan Little, Evan Anderson, Emmanuel Walter …
Prophylaxis with acetaminophen or ibuprofen for prevention of local reactions to the fifth diphtheria-tetanus toxoids-acellular pertussis vaccination: a randomized …
LA Jackson, M Dunstan, P Starkovich, J Dunn… - …, 2006 - publications.aap.org
BACKGROUND. The frequency of local vaccination reactions increases with successive
doses of diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccine, and local reactions …
doses of diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccine, and local reactions …
[HTML][HTML] A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants
…, D Peterson, J Dunn, SJ Hambidge, M Dunstan… - PLoS …, 2011 - journals.plos.org
Background Fever is common following infant vaccinations. Two randomized controlled trials
demonstrated the efficacy of acetaminophen prophylaxis in preventing fever after whole …
demonstrated the efficacy of acetaminophen prophylaxis in preventing fever after whole …
Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination
LA Jackson, P Starkovich, M Dunstan, O Yu… - …, 2008 - publications.aap.org
OBJECTIVE. Local reactions are relatively common after the fifth diphtheria-tetanus-acellular
pertussis vaccination, but factors associated with an increased risk of those reactions are …
pertussis vaccination, but factors associated with an increased risk of those reactions are …
Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
…, KM Neuzil, CG Whitney, P Starkovich, M Dunstan… - Vaccine, 2005 - Elsevier
In a phase I/II dose escalation study, varying volumes (0.1ml, 0.5ml, 1.0ml and 2.0ml) of 7-valent
pneumococcal conjugate vaccine (PCV) (Prevnar ® ) or 0.5ml of 23-valent …
pneumococcal conjugate vaccine (PCV) (Prevnar ® ) or 0.5ml of 23-valent …
Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A (H3N2) variant vaccine in healthy persons≥ 18 years old
…, F Munoz, J Wells, B Carste, M Dunstan… - The Journal of …, 2015 - academic.oup.com
Background. Variant influenza A(H3N2) viruses (H3N2v) have transmitted recently from pigs
to humans in the United States. Vaccines strategies are needed. Methods. Healthy adults …
to humans in the United States. Vaccines strategies are needed. Methods. Healthy adults …